Placebo-controlled three-armed pilot trial of Escitalopram or Nortriptyline for depressive symptoms in Parkinson’s disease (ADepT-PD)
AI Summary
Pilot randomised controlled trial of nortriptyline, escitalopram and placebo in Parkinson's disease; feasibility not met due to slow recruitment, so full trial halted.
At eight weeks depressive symptoms improved in all arms; nortriptyline showed greater PHQ-9 and Parkinson Anxiety Scale reductions versus placebo, escitalopram did not.
No differences on BDI-II between active drugs and placebo; small sample limits efficacy conclusions. Study dataset available at ClinicalTrials.gov NCT03652870.
J Neural Transm (Vienna). 2026 May 8. doi: 10.1007/s00702-026-03170-8. Online ahead of print.
ABSTRACT
Pilot randomised-controlled trial of nortriptyline and escitalopram compared to placebo for depressive symptoms in people with Parkinson’s disease (PD). Participants with PD and depressive symptoms received either nortriptyline, escitalopram or placebo with assessments at baseline and 8 weeks. Feasibility of the full trial was assessed using recruitment rate, loss to follow up before the 8-week primary endpoint, adherence to trial medication and rate of clinically significant adverse reactions. Intended efficacy outcomes included the BDI-II, Patient Health Questionnaire (PHQ-9), Parkinson Anxiety Scale (PAS), MDS-UPDRS and adverse effects. The aim was to recruit 46 participants to determine feasibility of the full trial. 52 participants were recruited from 24 NHS sites and randomised to nortriptyline (n = 16), escitalopram (n = 17) or placebo (n = 19). However, despite multiple strategies, recruitment took two years, and the study therefore did not reach its feasibility aim. Exploratory analyses showed that at 8 weeks depressive symptoms decreased significantly in all three arms. There was no difference in BDI-II score changes between the nortriptyline or the escitalopram when compared to the placebo arm, but PHQ-9 scores showed a greater reduction compared to placebo with nortriptyline (-3.4, 95% CI -5.75 to -0.95) but not with escitalopram (-1.2, 95% CI -3.54 to -1.17). Persistent Anxiety Scale scores showed a similar pattern (nortriptyline: -2.8, 95% CI -5.5 to -0.01; escitalopram: -2.2, 95% CI -4.9 to 0.05). As the study did not reach its primary aim of feasibility due to recruitment difficulties it did not continue to the full trial. The exploratory results are in keeping with previous studies suggesting a beneficial effect of nortriptyline on symptoms of depression and persistent anxiety. The small sample size however limits conclusions on efficacy and a beneficial effect of escitalopram is not excluded. STUDY DATASET IS AVAILABLE ON CLINICALTRIALS.GOV ID: NCT03652870, registered 29 August 2018.
Schizophr Bull. 2026 Apr 10;52(3):sbag064. doi: 10.1093/schbul/sbag064.ABSTRACTBACKGROUND AND HYPOTHESIS: Individuals with schizophrenia report that time can feel discontinuous. Difficulties in benefiting from the passage of...
Schizophr Bull. 2026 Apr 10;52(3):sbag068. doi: 10.1093/schbul/sbag068.ABSTRACTSTUDY DESIGN: In this secondary analysis of a randomized controlled trial, individuals aged 18-65 with a psychotic disorder and...
Schizophr Bull. 2026 Apr 10;52(3):sbag048. doi: 10.1093/schbul/sbag048.ABSTRACTBACKGROUND: According to predictive processing models, hallucinations can arise from over-weighting of prior expectations relative to sensory input. Individuals...
Schizophr Bull. 2026 Apr 10;52(3):sbag062. doi: 10.1093/schbul/sbag062.ABSTRACTBACKGROUND AND HYPOTHESIS: Persistent negative symptoms (PNS) often emerge early in the course of schizophrenia spectrum disorders, significantly impair...
Schizophr Bull. 2026 Apr 10;52(3):sbag067. doi: 10.1093/schbul/sbag067.ABSTRACTBACKGROUND: People with severe mental illness (SMI) are at an increased risk of infection mortality compared to the general...
Schizophr Bull. 2026 Apr 10;52(3):sbag049. doi: 10.1093/schbul/sbag049.ABSTRACTBACKGROUND AND HYPOTHESIS: The early phase of psychosis is critical for interventions to modify long-term outcomes. It is unclear...
